Trials / Recruiting
RecruitingNCT03715933
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 321 (estimated)
- Sponsor
- Inhibrx Biosciences, Inc · Industry
- Sex
- All
- Age
- 12 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INBRX-109 | Tetravalent DR5 Agonist Antibody |
| DRUG | Irinotecan | Chemotherapy |
| DRUG | Temozolomide | Chemotherapy |
| DRUG | carboplatin | chemotherapy |
| DRUG | pemetrexed | chemotherapy |
| DRUG | Leucovorin | chemotherapy |
| DRUG | Fluorouracil | chemotherapy |
Timeline
- Start date
- 2018-10-08
- Primary completion
- 2026-06-01
- Completion
- 2026-12-01
- First posted
- 2018-10-23
- Last updated
- 2026-03-18
Locations
35 sites across 6 countries: United States, France, Italy, Netherlands, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03715933. Inclusion in this directory is not an endorsement.